EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.
暂无分享,去创建一个
William Pao | Marc Ladanyi | Valerie Rusch | Gregory J Riely | M. Ladanyi | M. Kris | V. Rusch | W. Pao | Gregory Riely | V. Miller | M. Zakowski | D. Chitale | Allan R. Li | Allan R Li | Maureen F Zakowski | Mark G Kris | Vincent A Miller | Dhananjay Chitale
[1] D. Haber,et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] William Pao,et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Elisa Rossi,et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.
[4] Patricia L. Harris,et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Ladanyi,et al. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. , 2005, The Journal of molecular diagnostics : JMD.
[6] A. Iafrate,et al. Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma , 2007, Modern Pathology.
[7] J. Minna,et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.
[8] Sanja Dacic,et al. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. , 2006, American journal of clinical pathology.
[9] W. Gerald,et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations , 2005, Modern Pathology.
[10] Thomas LaFramboise,et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing , 2006, Nature Medicine.
[11] Chan Zeng,et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[13] Roy S Herbst,et al. KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer , 2007, Clinical Cancer Research.
[14] M. Meyerson,et al. A Rapid and Sensitive Enzymatic Method for Epidermal Growth Factor Receptor Mutation Screening , 2006, Clinical Cancer Research.
[15] William Pao,et al. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond , 2008, Modern Pathology.
[16] H. Varmus,et al. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.
[17] M. Ladanyi,et al. Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib , 2006, Clinical Cancer Research.
[18] M. Buyse,et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[20] T. Shibata,et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. Ladanyi,et al. Epidermal Growth Factor Receptor Mutation Testing in Lung Cancer: Searching for the Ideal Method , 2007, Clinical Cancer Research.
[22] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[23] H. Osada,et al. EGFR point mutation in non‐small cell lung cancer is occasionally accompanied by a second mutation or amplification , 2006, Cancer science.
[24] F. Hirsch,et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] M. Meyerson,et al. Epidermal Growth Factor Receptor Mutation Testing in the Care of Lung Cancer Patients , 2006, Clinical Cancer Research.